138402-25-2

Basic information

• Product Name: 2-Butyl-3-(2'-nitro-biphenyl-4-ylmethyl)-1,3-diaza-spiro[4.4]non-1-en-4-one
• Synonyms: 2-Butyl-3-(2'-nitro-biphenyl-4-ylmethyl)-1,3-diaza-spiro[4.4]non-1-en-4-one
• CAS NO: 138402-25-2
• Molecular Weight: 405.497
• Mol File: 138402-25-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-Butyl-3-(2'-nitro-biphenyl-4-ylmethyl)-1,3-diaza-spiro[4.4]non-1-en-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butyl-3-(2'-nitro-biphenyl-4-ylmethyl)-1,3-diaza-spiro[4.4]non-1-en-4-one(138402-25-2)
• EPA Substance Registry System: 2-Butyl-3-(2'-nitro-biphenyl-4-ylmethyl)-1,3-diaza-spiro[4.4]non-1-en-4-one(138402-25-2)

Safety Data

• Hazardous Substances Data: 138402-25-2(Hazardous Substances Data)

Upstream product

• 114772-39-3 4'-bromomethyl-2-nitrobiphenyl 
• 138402-05-8 2-butyl-1,3-diaza-spiro[4.4]non-1-en-4one 
• 624-31-7 4-tolyl iodide 
• 70680-21-6 4-methyl-2'-nitrobiphenyl 
• 609-73-4 o-nitroiodobenzene 

Downstream Products

• 197440-07-6 2-Butyl-3-[2'-(pyrrolidin-1-ylazo)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one 
• 197440-06-5 2-Butyl-3-(2'-iodo-biphenyl-4-ylmethyl)-1,3-diaza-spiro[4.4]non-1-en-4-one 
• 138401-24-8 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-[1,1'-biphenyl]-2-carbonitrile 
• 138402-26-3 3-(2'-Amino-biphenyl-4-ylmethyl)-2-butyl-1,3-diaza-spiro[4.4]non-1-en-4-one 

Relevant articles and documents

Radiosynthesis of [tetrazoyl-11C]irbesartan, a non-peptidic angiotensin II antagonist

With the aim of visualizing myocardial angiotensin II receptors (AT1 subtypes), [tetrazoyl-11C]2-n-butyl-1-[(2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl] - 4-spirocyclo-pentane-2-imidazoline-5-one ([tetrazoyl-11C]irbesartan (SR47436/BMS-186295)) 11 was synthesized in one pot in four steps from [11C]hydrogen cyanide. The labelling process which yielded [tetrazoyl-11C]irbesartan is described in detail and could be applied to the labelling of other ligands which possess the (1H-tetrazol-5-yl) moiety. Positron emission tomography (PET) studies were performed in dogs. Heart, lung and blood time-activity curves did not change. Therefore this new radioligand is not suitable for studying myocardial angiotensin II receptors with PET.